[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jakub Antczak\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,70,102,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100606670","polish-version-dyspnea-in-amyotrophic-lateral-sclerosis-100606670",false,"NCT07178574","Polish Version Dyspnea in Amyotrophic Lateral Sclerosis","Validation of Polish Language Version of Dyspnea in Amyotrophic Lateral Sclerosis Outcome Measure","Inclusion Criteria:\n\n* Diagnosis of definite ALS, or probable ALS or probable, laboratory supported ALS according to revised Escorial criteria \\[Brooks et al. 2000\\].\n* Complaining of dyspnea on exertion, or dyspnea at rest, or orthopnea without evidence of pulmonary or cardiac causes of dyspnea.\n\nExclusion Criteria:\n\n* Cognitive impairment severe enough to interfere with study process.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","Amyotrophic lateral sclerosis is a fatal disease with progressive degeneration of central and peripheral motor neurons. Weakness of pharyngeal and respiratory muscles lead to dyspnea, which is present in up to 80% of patients. Dyspnea in Amyotrophic Lateral Sclerosis (DALS-15) is a questionnaire designed to measure the severity of dyspnea. DALS-15 was originally created in German language. The aim of this study is to validate the Polish-language version of DALS-15.",[24],"Amyotrophic Lateral Sclerosis",[24,26,27,28,29],"dyspnea","DALS-15","validation","Polish-language version","NOT_YET_RECRUITING","2025-09-16",{"date":33,"type":34},"2025-09-19","ACTUAL",{"date":36,"type":20},"2025-10-01",{"date":38,"type":20},"2028-06-30",{"name":40,"class":41},"Jakub Antczak","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100567473","polish-version-fatigue-severity-scale-100567473","NCT06668649","Polish Version Fatigue Severity Scale","Validation of Polish Language Version of Fatigue Severity Scale","Inclusion Criteria:\n\n* Diagnosis of definite multiple sclerosis or definite, laboratory-supported multiple sclerosis, or definite amyotrophic lateral sclerosis, or probable amyotrophic lateral sclerosis or probable, laboratory supported amyotrophic lateral sclerosis or ischemic stroke or - for healthy controls - lack of diseases, pharmacotherapy or habits, which could induce abnormal tiredness\n\nExclusion Criteria:\n\n* Presence of cognitive deficits or behavioral disorder, which could disturb participation in the study.",true,{"count":51,"type":20},310,"Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis and other diseases with profound effect on quality of life and professional and social functioning. Not infrequent it is misdiagnosed as sleepiness or other symptom. Fatigue severity scale is a time efficient and easy to apply instrument to assess the impact of fatigue on patient's life. The aim of this study is to validate the Polish-language version of the Fatigue Severity Scale.",[54,24,55],"Multiple Sclerosis","Stroke, Ischemic",[57,54,58,59],"Fatigue","stroke","quality of life","RECRUITING","2024-11-07",{"date":63,"type":34},"2024-11-08",{"date":65,"type":34},"2024-11-04",{"date":67,"type":20},"2027-03-31",{"name":40,"class":41},2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100544627","effect-of-intermittent-and-continuous-theta-burst-stimulation-on-sleep-daytime-sleepiness-and-fatigue-in-depression-100544627","NCT06371352","Effect of Intermittent and Continuous Theta Burst Stimulation on Sleep, Daytime Sleepiness, and Fatigue in Depression","Effect of Intermittent and Continuous Theta Burst Stimulation on Sleep Quality, Sleep Propensity, Daytime Sleepiness, and Fatigue in Depression","Inclusion Criteria:\n\n* severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion\n* Diagnosis of major depression (F33.1 or F33.2) or bipolar disorder (F31.3 or F31.4).\n* The score of the Athens Insomnia Scale five or more\n* Unchanged antidepressive pharmacotherapy at least one month prior to inclusion\n\nExclusion Criteria:\n\n* Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy\n* Psychotic symptoms at the time of inclusion\n* Suicidal ideations and\u002For attempts within three months prior to inclusion","65 Years",{"count":79,"type":20},90,"INTERVENTIONAL",[82],"NA","Intermittent and continuous theta-burst stimulation (iTBS and cTBS respectively) are the newer modalities of transcranial magnetic stimulation with documented efficacy in treatment of depressed mood but with conflicting results regarding their efficacy in treatment of other symptoms of depression such as insomnia, daytime sleepiness and fatigue. This study will investigate the efficacy of iTBS over the left dorsolateral prefrontal cortex (DLPFC) and cTBS over the right DLPFC, compared to sham stimulation, in treatment of insomnia, daytime sleepiness and fatigue in depression.",[85,86],"Unipolar Depression","Bipolar Disorder",[85,86,88,89,90,91,92],"theta burst stimulation","sleep","sleepiness","fatigue","transcranial magnetic stimulation","2024-10-10",{"date":95,"type":34},"2024-10-15",{"date":97,"type":34},"2024-05-15",{"date":99,"type":20},"2027-05",{"name":40,"class":41},1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":109,"targetDuration":4,"studyType":80,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":101},"100544061","multisite-rtms-for-mood-cognitive-impairment-and-other-symptoms-of-depression-100544061","NCT06363981","Multisite rTMS for Mood, Cognitive Impairment and Other Symptoms of Depression","Multisite Repetitive Transcranial Magnetic Stimulation for Mood, Cognitive Impairment, Anhedonia and Disordered Sleep in Depressive Disorder","Inclusion Criteria:\n\n* severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion\n* Hamilton Depression Rating Scale between between 20 and 35 points at inclusion\n* The score in the Athens Insomnia Scale eight or more\n* The score of three or more points in items 4 and 21 of the Beck Depressions Inventory 2\n* Complaining about problems with memory and concentration timely related with the onset of depression\n\nExclusion Criteria:\n\n* Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy\n* Psychotic symptoms at the time of inclusion\n* Suicidal ideations and\u002For attempts within three months prior to inclusion",{"count":79,"type":20},[82],"Depressed mood is the main symptom of depression, but other symptoms like cognitive impairment, anhedonia or sleep disorders may also contribute to patients suffering and are difficult to treat. rTMS is a relatively novel treatment option, whose therapeutic potential is still investigated and optimized. The aim of this study is to assess the effect of rTMS applied over two stimulation sites on cognitive impairment, anhedonia and sleep disorders in depression.",[85,86],[114,115,116,117,118,119,120],"depression","repetitive transcranial magnetic stimulation","dorsolateral prefrontal cortex","dorsomedial prefrontal cortex","cognitive impairment","anhedonia","sleep disorders","2024-10-09",{"date":95,"type":34},{"date":124,"type":34},"2024-05-20",{"date":126,"type":20},"2027-04",{"name":40,"class":41},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":80,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":101},"100461964","analgesic-effect-of-accelerated-repetitive-transcranial-magnetic-stimulation-in-neuropathic-pain-100461964","NCT05295498","Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain","Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Pain Related to Peripheral Neuropathy","Inclusion Criteria:\n\n* Diagnosis of peripheral neuropathy\n* Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week\n* Score of 30 millimeter or more on the 100 millimeter visual analog scale of pain intensity at inclusion\n\nExclusion Criteria:\n\n* Severe depression\n* Personality disorders and other psychiatric conditions, which could disturb the participation in the study\n* Cognitive deficits, which could disturb the participation in the study\n* Epilepsy\n* Presence of magnetic material in the reach of magnetic field\n* Pregnancy\n* Likelihood to get pregnant\n* Intracranial electrodes",{"count":136,"type":20},70,[82],"Peripheral neuropathy is a frequent condition, commonly associated with pain. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. rTMS is usually performed once a day and the whole therapy of neuropathic pain lasts one week. In a number of recent clinical trials including patients with depression and some other disorders, rTMS was delivered several times a day, which reduced the time of the whole therapy. This approach was termed an accelerated rTMS. The purpose of this study is to investigate feasibility of accelerated rTMS in treatment of neuropathic pain.",[140],"Peripheral Neuropathy",[142,143,144,145],"Peripheral neuropathy","Neuropathic pain","rTMS","analgesic effect",{"date":93,"type":34},{"date":148,"type":34},"2022-11-04",{"date":150,"type":20},"2026-09-30",{"name":40,"class":41},""]